Integral Diagnostics Ltd · ASX:IDX
Integral Diagnostics — Shareholder Meeting (November 2022)
22 slides from Integral Diagnostics's shareholder meeting presentation, November 2022
Slide 1: 2022 Annual General Meeting Chair Address
Integral Diagnostics Limited 2022 Annual General Meeting Chair Address Slide 1 – Chair Address I am proud to be a part of a company whose purpose is to deliver the best possible outcomes for our patients by providing diagnostic imaging services, in order to diagnose and treat illness and injury. In
Slide 2: Chair Address: FY23 comments and acquisitions
Benowa and Burleigh Heads on the Gold Coast and O’Connor in Perth, which opened in October 2021, April 2022 and June 2022 respectively. IDX secured targeted acquisitions in existing geographies to expand the scope and depth of service locations to patients and broaden our referrer base. Now turning
Slide 3: Chair Address: ESG and thanks
The Board has continued the advancement of its environmental, social and governance (ESG) responsibilities and again produced a dedicated ESG Report in accordance with the Global Reporting Initiative (GRI) Standards: Core Option. Our Board approved ESG Strategy aligns with the United Nation’s Sustai
Slide 4: Managing Director and CEO Presentation
Integral Diagnostics Limited 2022 Annual General Meeting Managing Director and CEO Presentation Slide 4 - Managing Director and CEO Presentation Thank you, Helen and good morning, everyone. It’s good to see you all, in the room and online. I am also proud to be a part of a company working to build a
Slide 5: IDX Operates in Key Geographic Markets
Slide 7 - IDX Operates in Key Geographic Markets This table reflects the extent of our practices across Australia and New Zealand, including our most recent acquisitions. IDX now has 91 sites, 36 MRI’s and 6 PET-CT’s, soon to be 7 as we install a new PET-CT in Auckland next month. We are the number
Slide 6: Regulatory environment and PSMA PET CT scans
In NZ, the Accident Compensation Commission (ACC) has not applied indexation to radiology pricing in FY23. Private health funds, accounting for about 25% of our NZ payer base, have provided reasonable indexation. Slide 10 - PSMA PET CT Scans for Diagnosis of Metastatic Prostate Cancer Each AGM we li
Slide 7: Referral practices and over-utilisation of services
Referring to some recent Australian press articles where reports of alleged over-utilisation of services in the broader Medicare system have been called out. It is important to highlight that radiologists depend on referrals from GPs and other medical specialists and do not generate their own referr
Slide 8: IDX Focus in FY23
Slide 13 - IDX Focus in FY23 Our FY23 focus is on organic growth, integrating recent strategic acquisitions and executing selected greenfield and brownfield opportunities. We are investing in digital PET-CT services in Ballarat, Auckland and the Gold Coast, and investing in MRI in Bunbury, Torquay a
Slide 9: Chair Address
CHAIR ADDRESS Helen Kurincic
Slide 10: Financial Performance
FINANCIAL PERFORMANCE FY22 20.0% 46.2% 2.8% 26.1% 53.5% 43.1% decline in decline in increase in decline Net debt / decline in decline in operating operating operating in free cash EBITDA (pre- statutory NPAT operating NPAT EBITDA EPS revenue flow AASB16) $14.6m $21.7m $74.8m 10.2cps $358.7m $49.1m 1
Slide 11: Governance Highlights
GOVERNANCE HIGHLIGHTS Board • Governance model for our specialised medical business includes two Radiologist Executive Directors • New independent Non-Executive Director Andrew Fay commenced in July 2022 • Mr Fay is a highly experienced ASX Company Director with over 30 years experience in the finan
Slide 12: Managing Director & CEO Presentation
MANAGING DIRECTOR & CEO PRESENTATION Dr Ian Kadish
Slide 13: Delivering on Our Values in FY22
DELIVERING ON OUR VALUES IN FY22 • Served 800,000 patients • 245 reporting radiologists • 1,868 employees • Operating NPAT declined by • Managed workflows, personnel – 162 employees 43.1% to $21.7m in a COVID-19 and systems to continue to • Performed >2 million exams • Developed a Diversity & impact
Slide 14: Strong Historical Performance Track Record Impacted by COVID-19 in FY22
STRONG HISTORICAL PERFORMANCE TRACK RECORD IMPACTED BY COVID-19 IN FY22 Operating EBITDA ($m) Operating Revenue ($m) 358.7 93.5 348.8 75.7 74.8 274.1 231.0 53.0 188.0 38.1 FY18 FY19 FY20 FY21 FY22 FY18* FY19* FY20 FY21 FY22 Operating Diluted Earnings Per Share EBITDA Operating Margin (%) (cps) 19.0
Slide 15: IDX Operates in Key Geographic Markets
IDX OPERATES IN KEY GEOGRAPHIC MARKETS Western Victoria Queensland New Zealand Australia 5 5 Total IDX Geographic Queensland Western Victoria Victoria & NSW Queensland Queensland New Zealand New Zealand Market & NSW Australia Ballarat, Albury, Geelong, Wodonga, Sunshine Coast, Gold Coast, Brisbane,
Slide 16: DI Industry COVID-19 Impact: Australia
DI INDUSTRY COVID-19 IMPACT: AUSTRALIA Radiology growth since 1994 (with CAGR)* • FY22 was the most challenging year the industry has experienced. Australian industry revenue declined by 2.8% • Much of the decline was driven by the decrease in GP and specialist in-clinic consultations. In-clinic con
Slide 17: FY23 Regulatory Environment
FY23 REGULATORY ENVIRONMENT Australia: New Zealand: Medicare Changes • The Accident Compensation Commission (ACC) has not applied • MRI Licenses indexation to radiology pricing in FY23. Private health funds have provided indexation - On 1 November 2022 the MRI license regime will no longer apply in
Slide 18: PSMA PET-CT Scans for Diagnosis of Metastatic Prostate Cancer
PSMA PET-CT SCANS FOR DIAGNOSIS OF METASTATIC PROSTATE CANCER • Prostate cancer is the most common cancer in Australian men, >19,000 cases/year • The five-year survival from prostate cancer has improved from 59% to 95% • Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) an
Slide 19: FY23 External Environment
FY23 EXTERNAL ENVIRONMENT • The role that DI plays in early detection and prevention of disease • Immigration caps in Australia and New Zealand recently lifted. increasingly recognised: Doctor shortages are single biggest challenge in improving healthcare services in Australia and New Zealand - CT C
Slide 20: Strategy and YTD Trading Update
STRATEGY AND YTD TRADING UPDATE 1 Grow existing business and margin 2 Strategic acquisitions Strategy Accelerate use of Drive organic growth - teleradiology, digital Drivers of Nurture and develop including selective price and AI to improve the Drive our environmental, Focus on integrating recent st
Slide 21: IDX Focus in FY23
IDX FOCUS IN FY23 FY23 focus is on organic growth, integrating recent strategic acquisitions and select brownfield and greenfield opportunities AGM 2022 13
Slide 22: Slide 22
Integral Diagnostics — Shareholder Meeting (November 2022) on 6ix